Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program - Health News - redOrbit
Links shared publicly online about this topic.
- 95total visits
Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program - Health News - redOrbit
View full resource at redorbit.com
Tags: Obesity, Pharma, Healthy Living, News
Most Recently Shared on August 5, 2011 at 4:53 am By:
Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following... http://bit.ly/pnUdb1
Amylin And Takeda Discontinue Development Of
pharmaceuticalonline.com — “Amylin And Takeda Discontinue Development Of Pramlintide/Metreleptin Combination Treatment For Obesity Following Commercial Reassessment Of The Program - Amylin Pharmaceuticals” View full resource at pharmaceuticalonline.com
Most Recently Shared on August 8, 2011 at 5:22 pm By:
Amylin And Takeda Discontinue Development Of Pramlintide/Metreleptin Combination Treatment For Obesity Following... http://bit.ly/qIIhxi
Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program - Drugs.com MedNews
drugs.com — “Collaboration Will Explore Potential of Other Assets to Address Obesity Epidemic OSAKA, Japan, Aug. 5, Amylin Pharmaceuticals, Inc. (Nasdaq AMLN) and Takeda Pha” View full resource at drugs.com
Most Recently Shared on August 5, 2011 at 1:06 pm By:
Drugs and Devices OW OW Health
Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Fol... http://bit.ly/p1ft6q #drug
Advertisement
